We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 303

Compound patent held to be not soundly predicted for the level of promised utility found by the Court
  • Borden Ladner Gervais LLP
  • Canada
  • February 24 2016

The Federal Court has dismissed an application for prohibition concerning the drug ALIMTA. Although the parties joined issue on a significant number


Standard of Review of Palpable and Overriding Error Not Applied in Appeal from Rule 51 Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 27 2016

This is an appeal from the Federal Court's (FC) decision (2015 FC 797), which upheld the Prothonotary's decision allowing the generic Respondent's


Court grants prohibition order; finds allegations of obviousness, lack of utility and insufficiency not justified
  • Borden Ladner Gervais LLP
  • Canada
  • January 20 2016

In a decision issued on November 18, 2015, the Federal Court allowed the proceeding, granting Leo Pharma a prohibition order in relation to its


Supreme Court to Issue Decision in Leave Application Re Claim for Unjust Enrichment in S. 8 Proceeding
  • Borden Ladner Gervais LLP
  • Canada
  • January 13 2016

The Supreme Court of Canada has announced that on Thursday, January 14, 2016 it will issue its decision in Apotex' application for leave to appeal


Import Ban Quashed, and Health Canada Ordered to Retract Its Statements re Same
  • Borden Ladner Gervais LLP
  • Canada
  • January 13 2016

Apotex et al brought a judicial review of the Minister of Health's (the Minister) decision to impose an import ban on products from two of Apotex'


Court of Appeal states obviousness test is "more or less self-evident" and not "a fair expectation of success"
  • Borden Ladner Gervais LLP
  • Canada
  • January 6 2016

The Court of Appeal has dismissed the appeal of a dismissal of an application pursuant to thePM(NOC) Regulations that had found Mylan's allegations


Class action certification against Pfizer for an allegation of unlawful abuse of the patent system is overturned
  • Borden Ladner Gervais LLP
  • Canada
  • December 17 2015

The British Columbia Court of Appeal has overturned the certification of a class action relating to the drug Viagra, dismissing the action. The


Decisions re motions to strike upheld: Agreement with ratiopharm does not preclude Teva Section 8 Claim
  • Borden Ladner Gervais LLP
  • Canada
  • December 17 2015

The Pfizer appellants (Pfizer) appealed the decision of the Court denying their motion for summary judgment in respect of the action by Teva Canada


Decision to dismiss motion to strike portions of statement of defence and counterclaim upheld on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • December 17 2015

A Prothonotary dismissed a motion by Teva Canada Limited (Teva) to strike certain paragraphs in the statement of defence and counterclaim by the


Appeal from motion to compel answers arising from discovery dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • December 17 2015

The appellants (Hospira) brought a motion to compel answers to 354 questions refused or taken under advisement at the discovery of the Respondents